Home › Trials › NCT07497308
Clinical trial Recruiting at 1 site Observational Ages 18 and up

GDF-15 levels to predict early outcomes after LVAD implantation

Official title: Association of Preoperative GDF-15 Levels With Early Postoperative Outcomes and Mortality After LVAD Implantation

Run by Akdeniz University · NCT07497308 · Data updated 2026-11-12

We will see if pre-surgery blood levels of GDF-15 can predict early complications or death in adults having an LVAD implanted.

More Heart Failure trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment48 (estimated)
SponsorAkdeniz University
Academic / other
Locations1 site (Antalya, Please Select:)
StatusRecruiting
StartedFebruary 4, 2026
Main results expectedAugust 10, 2026
Study endsDecember 23, 2026
Registry record updatedMarch 27, 2026
Trial IDNCT07497308 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with advanced heart failure who are scheduled for LVAD implantation and can provide a preoperative blood sample and informed consent.

Probably not a fit

Patients under 18, those with active infection, active malignancy, severe hepatic failure, or missing required data are unlikely to benefit from GDF-15–based risk information in this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll adults with advanced heart failure who are scheduled to receive a left ventricular assist device at Akdeniz University. Preoperative serum GDF-15 will be measured and patients will be followed through the early postoperative period to record complications, mortality, and other short-term clinical outcomes. Statistical analyses will examine whether higher preoperative GDF-15 is associated with greater risk of early adverse events after LVAD surgery. The goal is to determine whether GDF-15 could improve preoperative risk stratification and inform perioperative management.

Why it matters

Potential benefit: If successful, preoperative GDF-15 measurement could help identify patients at higher risk for early complications or death and guide perioperative planning to improve outcomes.

How similar studies have gone: Previous research in heart failure and cardiac surgery populations has suggested GDF-15 has prognostic value, but its specific use for predicting early LVAD outcomes remains relatively untested.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:Adults aged 18 years and older

Patients with advanced heart failure undergoing LVAD implantation

Availability of preoperative GDF-15 measurement

Ability to provide written informed consent or consent provided by a legally authorized representative, according to local regulations -

Exclusion Criteria:Age under 18 years

Active infection

Active malignancy

Severe hepatic failure

Missing study data

Refusal to participate

\-

Where it's running

  • Akdeniz University, Faculty of Medicine, Department of Anesthesiology and Reanimation
    Antalya, Please Select:, Turkey (Türkiye)     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Advanced Heart Failure 7Akdeniz University 8
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.